Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Regina Paleski
Japanese big pharma Eisai taps Celgene and Sanofi execs as its new VPs for corporate affairs and market access. And Freeline Therapeutics, developer of gene therapies for bleeding disorders, selects a former Alnylam Pharma SVP as CEO.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Executives On The Move: Exits From Takeda Vaccines And Novartis Institutes To CMO Positions And Board Changes At Merck & Co.
Takeda Vaccines VP switches to cancer immunotherapy and vaccine company Bavarian Nordic and Novartis Institutes exec moves to molecular medicines firm Boston Pharmaceuticals, each in the CMO position. Meanwhile, Merck & Co will add a scientific and a strategic expert to its board.
Executives On The Move: Bayer Names Upcoming Information Chief And Legal Hires At Eli Lilly And CytoDyn
Stryker tech officer will become Bayer AG’s chief information technology and digital transformation Officer in June. In addition, monoclonal antibody therapy firm CytoDyn and global pharma Eli Lilly each hire a general counsel.
Executives On The Move: Gamida Cell Decides On Regulatory Appointment, Twist Bio Announces A Promotion And A VP Leaves Sanofi Genzyme For Krystal Biotech
Cellular and immune therapeutics company Gamida Cell has a new chief regulatory and quality officer and the SVP, R&D at Twist Biosciences steps higher to the chief operating officer position. At Sanofi Genzyme a genetic diseases VP leaves to become chief commercial officer at Krystal Biotech.
Gene-editing company Editas Medicine appoints a new CFO, while Affimed and NexImmune bring new chief medical officers on board.